Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jcin.2024.10.038 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
High Post-Transcatheter Aortic Valve Replacement Gradients: Not a Direct Predictor of Valve Deterioration.
Can J Cardiol
September 2025
Clinical Department of Cardiology and Cardiovascular Interventions, University Hospital, Krakow, Poland; 2(nd) Department of Cardiology, Institute of Cardiology, Jagiellonian University Medical College, Krakow, Poland. Electronic address:
Comparative 30-day Echocardiographic Outcomes of Myval versus Sapien and Evolut THVs: Insights from LANDMARK Trial.
Eur Heart J Cardiovasc Imaging
August 2025
Centre for Cardiovascular Medicine and Devices, William Harvey Research Institute, Queen Mary University of London and Barts Heart Centre, London, UK.
Introduction: Several factors, including device design, annulus size, and sizing strategies, influence transcatheter heart valve (THV) hemodynamic outcomes in patients with aortic stenosis(AS). This substudy evaluates early (30-day) echocardiographic outcomes of the Myval, Sapien, and Evolut THV series, focusing on hemodynamic performance and valve durability.
Methodology: The LANDMARK trial is a prospective, randomised, multicentre, open-label, non-inferiority trial comparing 384 patients implanted with Myval THV series to 384 receiving Sapien and Evolut THV series.
Early Hemodynamic Performance of the SAPIEN 3 Ultra Resilia and Evolut Valves: A Propensity-Matched Analysis.
Can J Cardiol
August 2025
Quebec Heart and Lung Institute, Laval University, Quebec City, Quebec, Canada; Clinic Barcelona, Barcelona, Spain. Electronic address:
Background: Limited data are available on early hemodynamic outcomes of the balloon-expandable SAPIEN 3 Ultra Resilia (S3UR) from Edwards Lifesciences (Irvine, CA) compared with the self-expandable Evolut (Medtronic, Dublin, Ireland) transcatheter heart valves. In this study we aimed to compare the hemodynamic performance of the S3UR with contemporary Evolut platforms (Evolut PRO, PRO+, FX) in a propensity-matched study.
Methods: A total of 307 patients who received an S3UR valve were matched with 488 patients who received Evolut valves (mean age, 80.
Perceval prosthesis implantation into challenging degenerated aortic valves: a literature review and case series.
J Cardiothorac Surg
August 2025
Department of Cardiothoracic Surgery, Townsville University Hospital, Queensland Health, Townsville, QLD, 4814, Australia.
Background: The Perceval Sutureless prosthesis can increase the effective orifice area (EOA) and reduce the chance of prosthesis-patient mismatch (PPM). This report presents three patients with challenging degenerated bioprosthetic valves undergoing redo aortic valve replacement (rAVR) using the Perceval (LivaNova, London, UK) prosthesis from a cohort of more than 300 performed cases and a review of the literature on the management of challenging degenerated valves.
Methods: Case 1: Degenerated 23 mm Trifecta with the valve cage densely adherent to the annulus.
Balloon-Expandable Versus Self-Expanding Valves in Bicuspid Aortic Stenosis: Insights From the SWEDEHEART Registry.
Catheter Cardiovasc Interv
August 2025
Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden.
Background: Transcatheter aortic valve replacement (TAVR) is increasingly used in patients with bicuspid aortic valve (BAV) stenosis, but there is limited comparative data on balloon-expandable (BEV) versus self-expanding valves (SEV) in this population.
Aim: To compare clinical and hemodynamic outcomes between BEVs and SEVs in patients with BAV stenosis.
Methods: This observational cohort included all patients who underwent TAVR in Sweden between 2016 and 2022.